Ingrezza Approved to Treat Tardive Dsykinesia
New Drugs , News / April 15, 2017

The FDA approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition. Tardive dyskinesia is a neurological disorder characterized by repetitive involuntary movement...

Sovaldi and Harvoni Approved for Pediatric Patients
Drug Alerts , News / April 15, 2017

The FDA approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults. These are ...

Dupixent Approved for Eczema
New Drugs , News / April 1, 2017

The FDA today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical t...

Skip to toolbar